BTG Acquires Novate Medical

 

September 7, 2018—BTG plc announced that it has acquired Novate Medical Ltd., a medical device company focused on the prevention of pulmonary embolism (PE) in patients at high risk of venous thromboembolic events.

Novate's Sentry bioconvertible inferior vena cava filter was recently granted FDA 510(k) regulatory clearance in the United States. Sentry's bioconversion feature eliminates the need for an additional interventional procedure to retrieve the device. Twelve-month clinical trial data for the device demonstrated no new symptomatic PE and no evidence of device migration, tilt, fracture, perforation, or embolization.

BTG plans to launch Sentry in the United States in the second half of fiscal year 2018/2019 and will sell the device through its existing vascular sales force.

The company paid $20 million in cash to acquire Novate, with additional cash considerations up to $130 million to be paid if certain commercial and sales-related milestones are met.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.